Figure 2.

Cyclooxygenase-2 (Cox-2) inhibitors do not significantly influence human B-cell viability or proliferation. Viability of human B cells was assessed by 7-aminoactinomycin D (7-AAD) exclusion. (a) Per cent viable cells analysed on days 2, 4 and 6 are represented as bar graphs for SC-58125 treatments. B cells were stained with carboxyfluorescein succinimidyl ester before agonist stimulation and SC-58125 treatment to analyse possible changes in proliferation by flow cytometry after 7 days of culture in two individual donors. Per cent divided cell gates were drawn based on undivided mitomycin-C-treated B cells. Vehicle-treated and SC-58125-treated B-cell CFSE profiles and per cent cells divided are shown for one representative donor (b) and per cent cells divided for multiple donors (n= 3) (c). Data are represented as mean ± SD.